Meet the innovators of AlveoliX

Passionate about science and driven by purpose, we work together 
to create safer, more personalized solutions for health challenges.

Meet the innovators of AlveoliX

Our vision

We want to make organs-on-chip technology the new standard for preclinical decision-making and bring data from bench to clinic. Our organs-on-chip will make drug discovery safer, better and personalized.

Meet our team

Our experienced team of biologists, engineers and clinicians is driven by innovation and patients’ needs. We are lucky to be able to make our passion our profession and are ready to push boundaries.
Giulia Raggi
Operations Manager & Scientific Project Lead
Andreas Hugi
CTO
Lea Lara De Maddalena
Operations Manager & Scientific Project Lead
Laurène Froment
Biologist & Laboratory Manager
Judith Kamper
Senior Laboratory Technician
Nicole Albrecher​
Biologist
Sina Zürcher
Junior Production Manager
Dr. Pauline Zamprogno
Products & Clients Manager
Dr. Nina Hobi
CEO & Scientific Director
Ferdinand Ativon
Head of Sales & Business Development
Severin Müller
Development Engineer

Advisory Board

Our scientific advisors, Prof. Olivier T. Guenat, Prof. Thomas Geiser and Prof. Ralph A. Schmid, promote organs-on-chip technology so that patients can rapidly reap the benefits of accelerated drug discovery. They initiated the years-long partnership with the Inselspital, Switzerland’s largest hospital group, and the ARTORG Center of the University of Bern.

Thomas Geiser | Prof. Dr. med.
Clinical Director and Head of Pulmonary Medicine, Inselspital Head of the Lung Research Laboratory, University of Bern
«Lung-on-chip technology will push precision medicine forward – in favor of patients with acute and chronic lung diseases.»
Olivier T. Guenat | Prof. Dr.
Group Head Organs-on-Chip Technology, University 
of Bern
«In 2010, the idea sparked to bio-engineer the human breathing motion. Now, this cutting-edge technology made its first step into the drug approval process.»
Ralph A. Schmid | Prof. Dr. med. em.
Clinical Director em. General Thoracic Surgery, Inselspital
«Surgery can cure cancer in early stages, but additional, innovative therapies are needed to improve survival in late stages. We are testing the safety and efficacy of novel cancer drugs in the lung-on-chip.»

Careers

AlveoliX stands up for diversity, equality, and tolerance. Are you ready to drive the development of new technologies with us? Together, we can transform the drug development process.
We don’t have open position at the moment.

News & Events

Explore the science, inspiring stories, and media coverage that showcase our innovations, share our journey, and bring our vision to life.
News
Events
FDA
WiFIX – 1M Eurostars grant
European WiFIX consortium awarded EUR 1 M Eurostars grant to develop Nexopore, a novel delivery technique for nucleic acid therapeutics Copenhagen/Vilnius/Berne, June 9 2026: A European consortium has been awarded Eurostars funding for WiFIX, a project that aims to overcome the current delivery challenges holding back widespread adoption of nucleic acid therapeutics. It brings together...
Read now
We founded IAMPS
🚀 Big news for the MPS community: the Industry Alliance for Microphysiological Systems (IAMPS) is officially launched. 🤝 Today is a key moment for Europe’s life sciences ecosystem. AlveoliX, BiomimX® Srl, chiron, Dynamic42 GmbH, InSphero, MIMETAS, NETRI, React4life and TissUse GmbH just founded the world’s first industry association dedicated to representing MPS providers. 💬 Our...
Read now
We made the cover of Science Advances!
📰The manuscript “Autologous human iPSC-derived alveolus-on-chip reveals early pathological events of Mycobacterium tuberculosis infection” has just been published in Science Advances and made the cover Science Advance! 🎯The Francis Crick Institute has demonstrated that our Lung-On-Chip model can faithfully replicate early stages of human lung infection. Key highlights:✅ Human relevance: A fully human, iPSC-derived alveolus-on-chip...
Read now
STA Finalist
🎉 Big news: We are a finalist! hashtag#STA2025 🤩 We are really exited to announce that we have been selected as a finalist for the Swiss Technology Awards 2025 — one of the most prestigious distinctions for innovation and technology transfer in Switzerland. 🙏 A huge thank you to the jury and organizers for giving...
Read now
Show more
Where to see us in 2026
We are looking forward to meeting you at the following events: 📍 SOT 2026: March 22–25, San Diego📍 3RLand: March 24–26, Tübingen📍 SwissBiotech: May 4–5, Basel📍 MPS: May 26–29, Washington📍 EUROoC: June 22–24, Braga📍 EUROTOX: September 13–16, Vienna📍 LIVe: October 8–9, Geneva📍 ESMO: October 23–27, Madrid See you soon! ✨
Read now
SOT 2026
San Diego, 22-25 March 🚀 Less than two weeks to go until SOT in San Diego! 🔬 Come meet our team at booth 1436 and learn more about our latest work. If you work in toxicology, safety assessment, efficacy studies, inhalation research, or fundamental research, stop by to discuss how we can support your work....
Read now
NSL Day 2025
13-14 October- Gothenburg, Sweden 🚨The Nordic Life Science Days are approaching ! 📍Join us at the largest Nordic partnering event for life science in Gothenburg on 13-14 October. This event brings together decision-makers from biotech, medtech, pharma, research and beyond— a perfect opportunity to connect and share ideas. 🌟As part of the Swiss Delegation, we...
Read now
ERS 2025
September 27- October 1- Amsterdam, Netherland ✨ Next stop: ERS Congress, Amsterdam! 📍  We look forward to discussing the latest advances in respiratory medicine and science with the world’s leading respiratory experts. 🔬 Meet Ferdinand Ativon and discover how our  AXBarrier-on-chip can accelerate drug safety, efficacy, and MoA insights in rare lung diseases. 📑 Don’t...
Read now
Show more
EU adopts roadmap to phase out animal testing
The European Commission published a roadmap covering 15 domains, including chemicals, pesticides, pharmaceuticals, and food additives, with over 30 key recommendations to move toward non-animal methods. RAPS
Read now
FDA targets oncology drug development
The FDA proposed targeted guidance to reduce animal testing in oncology, aiming to streamline the drug development process without compromising patient safety. RAPS
Read now
FDA issues draft guidance on New Approach Methodologies
The FDA opened the door to organ-on-chip and AI-based methods in drug development. By early 2026, FDA reported 151 NAM-related tools in the qualification pipeline. IntuitionLabs
Read now
UK backs human in-vitro models with new funding
The MRC, Innovate UK, and the Wellcome Trust committed funding to advance organ-on-chip models, with 5 UK teams focusing on liver, brain, cancer, pain and blood vessel disease models. HM Revenue and Customs
Read now
Show more

Our partners

01
Alexis Technologies

Alexis is an innovative biotech startup based in Bern. They develop advanced in-vitro inhalation and organ‑on‑chip models focusing on lung exposure, aimed at reducing animal testing and improving drug safety evaluations.
They offer contract research services: pre‑clinical inhalation toxicology testing for inhalable drugs, nano‑particles, chemical aerosols, environmental pollutants, nicotine products, and more

Learn More
02
Vitrocell
03
Artorg Center

Support & Collaborations

Ready to See It in Action?

Let’s streamline your discovery pipeline with our Organ-on-Chip platform. Lung, Gut, Liver, and more - fully human, fully ready.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Please find more information in our privacy policy

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

This website uses HubSpot to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.